William Mullaney has resigned from the board of directors ofAprogenex Inc. Mullaney, who is a managing partner of VenturesMedical L.P., is leaving his position at the Houston company becausehis venture capital fund's interest in Aprogenex has been acquiredby a third party.
Julius Vida, who recently retired as vice president of businessdevelopment of Bristol-Myers Squibb Co., joined the board ofdirectors of Princeton, N.J.-based Medarex Inc.
Richard Krawiec has joined Amylin Pharmaceuticals Inc. of San Diegoas director of corporate communications. Krawiec was director ofinvestor relations and corporate communications at IdecPharmaceuticals Corp.
Hyseq Inc. of Chicago has named Garrison E. Bielen president andchief executive officer. His previous positions included corporate vicepresident and president of the Sorenson Research Division of AbbottLaboratories and senior vice president at United Research Inc. Inaddition, James Rathmann, general partner at Falcon TechnologyPartners LP, has been elected to Hyseq's board of directors.
Christopher Edge has been appointed senior scientist at OxfordGlycoSystems Ltd of Abingdon, Oxon, United Kingdom. He joins thecompany from the University of Oxford Glycobiology Institute.
Magainin Pharmaceuticals of Plymouth Meeting, Pa., has electedBernard Canavan to its board of directors. He recently retired aspresident of American Home Products Corp.
(c) 1997 American Health Consultants. All rights reserved.